Skip to Main Content

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing

February 1, 2022

Dear Provider,

The Health Plan is implementing the following policy for Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing with an effective date as of May 1, 2022.

Summary of Payment Edit:

The Health Plan will be limiting payment for GI pathogen panels of 12+ targets (CPT 87507 and 0097U) to inpatient settings, including inpatient hospital (POS 21), emergency department (POS 23), and outpatient hospital (POS 22).

CPT® Codes



Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets


Gastrointestinal pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 22 targets (Campylobacter [C. jejuni/C. coli/C. upsaliensis], Clostridium difficile [C. difficile] toxin A/B, Plesiomonas shigelloides, Salmonella, Vibrio [V. parahaemolyticus/V. vulnificus/V. cholerae], including specific identification of Vibrio cholerae, Yersinia enterocolitica, Enteroaggregative Escherichia coli [EAEC], Enteropathogenic Escherichia coli [EPEC], Enterotoxigenic Escherichia coli [ETEC] lt/st, Shiga-like toxin-producing Escherichia coli [STEC] stx1/stx2 [including specific identification of the E. coli O157 serogroup within STEC], Shigella/Enteroinvasive Escherichia coli [EIEC], Cryptosporidium, Cyclospora cayetanensis, Entamoeba histolytica, Giardia lamblia [also known as G. intestinalis and G. duodenalis], adenovirus F 40/41, astrovirus, norovirus GI/GII, rotavirus A, sapovirus [Genogroups I, II, IV, and V])

What does this mean for providers?

The Health Plan will deny payment for CPT code 87507 and HCPCS code 0097U when billed outside of the following places of service: inpatient hospital (21), outpatient hospital/observation (22), and ED (23). Note: these large panels are appropriate for diagnostic information for members in critical care or who are immune compromised.

If a provider does not agree with the Health Plan’s decision, they may dispute or appeal the denial. The Health Plan will require medical records that substantiate provider billing.

We are here to help. Please contact your Network Representative for general inquiries regarding this program.


Centene Corporation